Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03514875
Recruitment Status : Not yet recruiting
First Posted : May 2, 2018
Last Update Posted : October 16, 2019
Sponsor:
Information provided by (Responsible Party):
Song-Young Park, University of Nebraska, Omaha

Brief Summary:
Neurodegenerative diseases such as Mild Cognitive Impairment, Alzheimer's, and dementia affect millions of Americans. Although these diseases are heavily researched, there is very little research examining the impact of attenuated carotid artery endothelial function and cerebrovascular blood flow on cognitive function. This is surprising, as cerebrovascular oxygenation has been shown to be strongly associated with reduced cognitive function and the pathogenesis of neurodegenerative diseases. For example, hypertension, diabetes, and high cholesterol have been shown to increase the risk of Alzheimers related dementia. Therefore, the purpose of this proposed study will be to examine the effects of MitoQ supplementation on carotid artery vasodilatory function and cerebrovascular blood flow in those suffering from Mild Cognitive Impairment (MCI). MitoQ is a mitochondria-targeting antioxidant that can improve nitric oxide production in the blood vessel, which should improve endothelial function, and thus cerebrovascular blood flow.

Condition or disease Intervention/treatment Phase
Alzheimer Disease, Early Onset Mild Cognitive Impairment Dietary Supplement: MitoQ Dietary Supplement: Placebo Not Applicable

Detailed Description:

Metabolic disease parameters, such as hyperlipidemia and hypertension have been observed in Alzheimer's disease and dementia. The causes of neurodegenerative diseases like Alzheimers are not completely understood. However, increasing amounts of evidence are pointing to vascular dysfunction as a cause of this disease. Known as the vascular hypothesis, pathology is suggested to begin with cerebral hypoperfusion through attenuated blood flow via clogged carotid arteries. Hypoperfusion of cerebral cells means that they do not receive enough oxygen to function optimally. This lack of oxygen is believed to lead to cognitive impairment. It is hypothesized that these metabolic conditions can damage the endothelial wall, leading to impaired vasodilation and blood flow. This damage occurs in the carotid arteries, which would limit blood flow to the brain. This impaired blood flow also results from higher levels of reactive oxygen species (ROS), which reduce the bioavailability of nitric oxide (NO), an important vasodilator. Antioxidants, such as MitoQ, reduce these ROS and thus increase the NO availability, which improves endothelial function. This study will measure the use of the antioxidant MitoQ to reduce this endothelial dysfunction, thereby improving blood flow in the carotid arteries. Blood vessel health can be measured by how much bigger or smaller a vessel can become, because the ability of the vessel to change size is very important to make sure that blood is delivered to the tissues of the body. This study is being done to help us understand if endothelial dysfunction in Mild Cognitive Impairment (MCI) patients leads to the pathogenesis of the disease.

We will examine how endothelial function and cerebrovascular blood flow changes after consumption of MitoQ. We hope to achieve this through measures of carotid artery blood flow and brachial artery blood flow, using a doppler ultrasound for both, while using flow mediated dilation when measuring the brachial artery. The flow-mediated dilation test is a validated and safe assessment of endothelial function and vascular health. The premise behind the assessment is that endothelium produces autocoids, like nitric oxide, that dilate in response to shear stress. Flow-mediated dilation has been shown to be an effective tool to assess endothelial function in the peripheral and coronary vasculature. This assessment of endothelial health can be used in healthy individuals to detect risk for cardiovascular disease. We will also utilize near infrared spectroscopy to measure tissue oxygenation in the brain, which is also a measure of improved blood flow, and will measure brain neural activity with an EEG. Finally, we will collect blood samples to measure the change in ROS levels before and after MitoQ consumption


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: 1:1 Randomized, cross-over design
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Mitochondrial-targeted Antioxidant on Carotid Artery Endothelial Function and Brain Blood Flow in Mild Cognitive Impairment (MCI) Patients
Estimated Study Start Date : November 11, 2019
Estimated Primary Completion Date : May 1, 2020
Estimated Study Completion Date : October 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antioxidants

Arm Intervention/treatment
Experimental: MitoQ-Placebo
Subjects will be tested on two different days, first day will be baseline and MitoQ intake, and second day will be placebo intake. Testing will take place 40-minutes after MitoQ and placebo intake. There will be a 2-week washout between testing days.
Dietary Supplement: MitoQ
MitoQ is a mitochondria-targeting antioxidant, which should improve NO bioavailability, and therefore vasodilation

Dietary Supplement: Placebo
A placebo will be used in a double blinded, randomized, cross-over design

Experimental: Placebo-MitoQ
Subjects will be tested on two different days, first day will be baseline and placebo intake, and second day will be MitoQ intake. Testing will take place 40-minutes after placebo and MitoQ intake. There will be a 2-week washout between testing days.
Dietary Supplement: MitoQ
MitoQ is a mitochondria-targeting antioxidant, which should improve NO bioavailability, and therefore vasodilation

Dietary Supplement: Placebo
A placebo will be used in a double blinded, randomized, cross-over design




Primary Outcome Measures :
  1. Carotid artery blood flow [ Time Frame: 2 Days ]
    Blood flow in the carotid artery will be measured with ultrasound


Secondary Outcome Measures :
  1. Oxidative Stress [ Time Frame: 2 days ]
    Blood draws will be taken to measure oxidative stress markers in the blood

  2. Cerebrovascular Oxygenation [ Time Frame: 2 Days ]
    Near-infrared spectroscopy will be used to measure cerebrovascular oxygenation

  3. Brain Electrical Activity [ Time Frame: 2 Days ]
    EEG will measure brain electrical activity

  4. Endothelial Function [ Time Frame: 2 Days ]
    Flow-mediated dilation will be used to measure vasodilation in the brachial artery



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. be able to give written, informed consent
  2. Have a clinical diagnosis of Mild Cognitive Impairment (MCI) verified by a medical doctor
  3. have a stable blood pressure regimen, stable lipid regimen, stable diabetes regimen and risk factor control for 6 weeks.
  4. Free of kidney, metabolic or cardiovascular disease, including hypertension (stage 2) and previous cardiac events
  5. be between 50-85 years old

Exclusion Criteria:

  1. All participants must be free from smoking and alcohol abuse
  2. Not be taking prescription drugs (other than oral contraceptives, blood pressure lowering drugs, and metformin)
  3. Must not be diagnosed with Alzheimer's disease.

Publications:
Layout table for additonal information
Responsible Party: Song-Young Park, Principal Investigator, University of Nebraska, Omaha
ClinicalTrials.gov Identifier: NCT03514875     History of Changes
Other Study ID Numbers: UNOmaha3
First Posted: May 2, 2018    Key Record Dates
Last Update Posted: October 16, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cognitive Dysfunction
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs